Core Viewpoint - The company has completed a share buyback and cancellation process, reducing its total share capital from 810 million shares to 808 million shares through the repurchase of 1.4767 million shares, which represents 0.1824% of the total shares before cancellation [1] Group 1 - As of August 20, 2025, the company repurchased a total of 1.4767 million shares through a dedicated securities account via centralized bidding [1] - The repurchased shares accounted for 0.1824% of the company's total share capital prior to cancellation, which was 810 million shares [1] - The cancellation of the repurchased shares was completed on August 22, 2025, with the total share capital adjusted to 808 million shares [1]

Core Viewpoint - The company has approved the cancellation of 112,750,413 repurchased shares, reducing its total share capital and registered capital, which will enhance earnings per share and shareholder returns without significantly impacting its financial status or operations [1][4]. Group 1: Share Repurchase Implementation - The company initiated a share repurchase plan on November 11, 2021, with a budget between RMB 800 million and RMB 1.5 billion, at a maximum price of RMB 6.50 per share, within a 12-month period [1][2]. - By November 10, 2022, the company had repurchased a total of 112,750,413 shares, accounting for approximately 4.51% of the total shares before cancellation, with a total transaction amount not specified [2][3]. Group 2: Reasons and Quantity for Cancellation - The shares were intended for employee stock incentive plans, but due to the expiration of the three-year period without implementation, the company decided to cancel these shares [2][3]. Group 3: Changes in Share Capital Structure - After the cancellation, the total number of shares will decrease from 2,500,783,182 to 2,388,032,769, with limited and unrestricted shares adjusted accordingly [3][4]. - The structure will reflect 74,950,521 shares with limited sale conditions (3.14%) and 2,313,082,248 unrestricted shares (96.86%) post-cancellation [3]. Group 4: Impact and Future Arrangements - The cancellation is expected to improve earnings per share and will not affect the company's financial condition or future development significantly [4]. - The company will apply for share cancellation procedures and make necessary amendments to its articles of association and business registration following shareholder approval [4].

Core Viewpoint - Shanghai Cambridge Technology Co., Ltd. has completed the registration of changes in its business license, reflecting a reduction in registered capital and adjustments to its governance structure following the implementation of a restricted stock incentive plan [1][2]. Group 1: Business Changes - The company held two extraordinary general meetings on November 30, 2022, and June 16, 2025, to approve the stock incentive plan and the reduction of registered capital [1]. - The total share capital has been reduced from 268,041,841 shares to 268,019,841 shares, and the registered capital has decreased from RMB 268,041,841 to RMB 268,019,841 [2]. Group 2: Shareholder Information - Cambridge Industries Company Limited, the controlling shareholder, held 36,556,453 shares (13.64% of total shares) before the changes, while Shanghai Kangling Technology Partnership held 5,918,476 shares (2.21%) [7]. - After the changes, the combined shareholding of the information disclosure obligors decreased from 15.85% to 15.00% of the total shares [8][10]. Group 3: Future Plans - The information disclosure obligors have no plans to increase their shareholding in the next 12 months [10]. - A reduction plan was disclosed on May 13, 2025, allowing for a maximum reduction of 8,041,254 shares (2.00% of total shares) within three months [11].

Group 1 - The company plans to change the purpose of repurchased A-shares from employee stock ownership plan to cancellation and reduction of registered capital, involving the cancellation of 67,786,990 shares [1] - After the cancellation, the company's total share capital is expected to be reduced, with specific details provided in the announcement dated August 19, 2025 [1] - The company is also proposing amendments to its Articles of Association in accordance with relevant laws and regulations due to changes in registered capital [2]

Group 1 - The company has changed the purpose of its share repurchase plan, now intending to use the repurchased shares for capital reduction instead of employee stock ownership plans [1] - A total of 6,379,004 shares will be canceled, leading to a corresponding reduction in the company's registered capital [2] - The final situation of the company's capital changes will be confirmed by the China Securities Depository and Clearing Corporation after the completion of the cancellation process [2] Group 2 - The company is notifying creditors about the capital reduction, allowing them to claim their debts within 45 days from the announcement [2] - Creditors must provide relevant documentation to assert their claims, including contracts and proof of debt relationships [3] - Specific requirements for both corporate and individual creditors are outlined for submitting claims [3]

Core Viewpoint - The company, Buchang Pharma, is demonstrating long-term confidence in its value by announcing the cancellation of repurchased shares, which reflects its commitment to shareholder returns and social responsibility [1][2]. Group 1: Share Repurchase and Cancellation - Buchang Pharma plans to cancel 51,474,203 repurchased shares, which accounts for 4.65% of the total shares before cancellation, reducing the total share capital from 1,106,042,645 to 1,054,568,442 shares [1]. - Since its listing, the company has conducted three share repurchases, totaling 87,012,200 shares and spending 1,744.43 million yuan, with 35,538,000 shares already canceled [2]. - The cancellation of shares is expected to enhance earnings per share and net asset value, stabilize stock prices, and reflect the company's financial health and cash flow [2]. Group 2: Financial Performance and Shareholder Returns - The company has approved a mid-term dividend plan for 2025, reinforcing its commitment to returning value to shareholders, with cumulative dividends exceeding 7.5 billion yuan since its establishment [2]. - Buchang Pharma has paid over 32 billion yuan in taxes and has contributed to local economic development through job creation [3]. Group 3: Industry Position and Product Development - With over 30 years in the traditional Chinese medicine sector, Buchang Pharma has developed a diversified portfolio across various pharmaceutical categories, becoming a leading innovator in traditional Chinese medicine [4]. - The company holds 468 valid patents and is advancing 213 research projects, focusing on major diseases and cultivating significant products [4]. - Recent international approvals for products like the "Stabilizing Heart Granules" in Malaysia and "Pulmonary Detox Granules" in Canada, Kazakhstan, and Uzbekistan indicate the company's global expansion efforts [5]. Group 4: Vision and Social Responsibility - Buchang Pharma aims to be "China's Johnson & Johnson, and the world's Buchang," emphasizing its commitment to social responsibility and innovation in the healthcare sector [5].

证券代码：603158 证券简称：腾龙股份 公告编号：2025-041 二、需债权人知晓的相关信息 由于公司本次回购注销部分股权激励股份将导致注册资本减少，根据《中华 人民共和国公司法》等相关规定，公司债权人自接到公司通知起30日内、未接到 通知者自本公告披露之日起45日内向本公司申报债权，并有权凭有效债权文件及 相关凭证要求公司清偿债务或者提供相应担保。债权人如逾期未向公司申报债权， 不会因此影响其债权的有效性，相关债务义务将由公司根据原债权文件的约定继 续履行。公司本次回购注销将按法定程序继续实施。 公司债权人如要求公司清偿债务或提供相应担保的，应根据《中华人民共和 国公司法》等法律、法规的有关规定向公司提出书面要求，并随附有关证明文件。 债权人可采用信函或传真的方式申报，债权申报所需材料：公司债权人可持证明 债权债务关系存在的合同、协议及其他凭证的原件及复印件到公司申报债权。债 权人为法人的，需同时携带法人营业执照副本原件及复印件、法定代表人身份证 明文件；委托他人申报的，除上述文件外，还需携带法定代表人授权委托书和代 理人有效身份证的原件及复印件。债权人为自然人的，需同时携带有效身份证的 原件及复印件 ...

Core Viewpoint - The company will cancel 51,474,203 repurchased shares, accounting for 4.65% of the total shares before cancellation, reducing the total share capital from 1,106,042,645 shares to 1,054,568,442 shares after the cancellation [2][7]. Group 1: Share Repurchase and Cancellation Details - The company approved a share repurchase plan on December 13, 2023, with a total fund of no less than 180 million yuan and no more than 360 million yuan, with a maximum repurchase price of 24 yuan per share [3]. - The repurchase amount was later increased to between 360 million yuan and 720 million yuan, with the company completing the repurchase by November 6, 2024, acquiring 44,853,573 shares at an average price between 14.16 yuan and 17.44 yuan, totaling approximately 712.38 million yuan [3][4]. - A second repurchase plan was approved on December 26, 2024, with a total fund of no less than 50 million yuan and no more than 100 million yuan, with a maximum price of 23 yuan per share, resulting in the acquisition of 6,620,630 shares by May 9, 2025, at prices between 13.86 yuan and 15.07 yuan, totaling approximately 98.06 million yuan [4]. Group 2: Approval and Legal Compliance - The cancellation of repurchased shares was approved in meetings held on April 25 and May 26, 2025, with the purpose of reducing registered capital [5]. - The company will follow relevant laws and regulations for the cancellation process, with the cancellation expected to be completed on August 12, 2025 [7]. - The company has notified creditors regarding the cancellation, and no requests for early debt repayment or guarantees were received within the stipulated period [7].

关于注销回购股份的实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603858 证券简称：步长制药 公告编号：2025-145 山东步长制药股份有限公司 重要内容提示： ●公司将注销 51,474,203 股已回购股份，占注销前公司总股本的比例为 ●回购股份注销日期：2025 年 8 月 12 日 一、股份回购方案及实施情况 山东步长制药股份有限公司（以下简称"公司"）于 2023 年 12 月 13 日召 开第四届董事会第四十七次会议，审议通过了《关于以集中竞价交易方式回购股 份的方案的议案》，同意公司使用自有资金以集中竞价交易方式回购社会公众股 份。本次回购的资金总额不低于 1.80 亿元，不高于 3.60 亿元，回购价格上限为 票的公司债券。公司于 2024 年 6 月 14 日召开第四届董事会第五十六次会议，审 议通过了《关于增加股份回购金额的议案》，同意股份回购金额由原来 1.80-3.60 亿元增加至 3.60-7.20 亿元，原回购股份的方案中其他内容不变。截至 2024 年 股份 44,85 ...

Group 1 - The company has decided to cancel 10,000,053 repurchased shares and reduce its registered capital by the same amount, following the approval from the board and shareholders [1] - The cancellation of shares is due to the expiration of the three-year holding period for the repurchased shares, during which the company did not implement any employee stock ownership or incentive plans [1] - The company is complying with relevant laws and regulations regarding share repurchase and capital reduction [1] Group 2 - Creditors have the right to request debt repayment or guarantees within 45 days from the announcement date, with specific procedures outlined for submitting claims [2] - The company has provided contact information and requirements for creditors to submit their claims, including necessary documentation [2][3] - The announcement emphasizes that the validity of creditors' claims will not be affected if they fail to apply within the specified period [2]